Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173 -activating mutations in 3 children
- 1 December 2016
- journal article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 138 (6), 1752-1755
- https://doi.org/10.1016/j.jaci.2016.07.015
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Cytomegalovirus Retinitis in a Patient Who Received RuxolitinibNew England Journal of Medicine, 2016
- Parsing the Interferon Transcriptional Network and Its Disease AssociationsCell, 2016
- Stimulator of Interferon Genes–Associated Vasculopathy With Onset in InfancyJAMA Dermatology, 2015
- Aicardi–Goutières syndrome and the type I interferonopathiesNature Reviews Immunology, 2015
- A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)Pediatric Blood & Cancer, 2015
- Remission of Recalcitrant Dermatomyositis Treated with RuxolitinibNew England Journal of Medicine, 2014
- Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestationsJCI Insight, 2014
- Activated STING in a Vascular and Pulmonary SyndromeNew England Journal of Medicine, 2014
- Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control studyThe Lancet Neurology, 2013
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012